Secular trends in cytomegalovirus (CMV) risk and outcomes: results from a 10-year longitudinal cohort study in adult kidney transplant recipients
- PMID: 39903380
- DOI: 10.1007/s11255-025-04399-0
Secular trends in cytomegalovirus (CMV) risk and outcomes: results from a 10-year longitudinal cohort study in adult kidney transplant recipients
Abstract
Background: The goal of this study was to determine the secular trends in the incidence of CMV sero-mismatch (D+/R -) and if these trends meaningfully impact clinical outcomes.
Methods: This was a single-center longitudinal cohort study in adult kidney recipients transplanted between Jan 2012 and June 2021 with follow-up through June 2022. Baseline and follow-up data were collected. Univariate and multivariate statistics were used to analyze the data.
Results: 2,392 kidney transplants were performed during the study period; 132 patients did not meet inclusion criteria. The mean age was 52 years, 41% were female, 57% were black, and 19% were CMV D + /R -. The odds of being CMV high-risk increased by 6% each year (OR 1.06, 1.02-1.10 p = 0.003); 48% of the variability associated with CMV serostatus was explained by transplant year (R2 = 0.478, p = 0.002). Sequential modeling demonstrated that CMV D + /R - serostatus was a substantial risk factor for CMV infection (HR 5.7, 4.5-7.3), CMV disease (HR 8.4, 3.9-18.0), CMV resistance (HR 17.9, 3.8-84.2), CMV refractory infection (HR 35, 4-280), late CMV infection (HR 12.0, 8.3-17.1), acute rejection, and hospitalization for opportunistic infections. Secular trend analysis demonstrated that CMV infections, CMV resistance, and late CMV increased in incidence since 2012. The risks of CMV resistance and late infection was significantly influenced by D + /R - serostatus and transplant year, indicating that this risk is worsening over time.
Conclusion: The CMV D + /R - serostatus remains the single most important risk factor for CMV infection, disease, resistance, refractory infection, and late CMV, which appears to be increasing in magnitude.
Keywords: CMV; Cytomegalovirus infections; Follow-up studies; Kidney; Kidney transplantation; Longitudinal studies; Opportunistic infections; Risk factors; Secular; Transplant.
© 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Declarations. Conflict of interest: Ms Perry, Drs Soliman and Taber are current employees of the United States Veterans Health Administration. However, the opinions and views expressed in this paper are the Authors’ own and do not represent the official views or policies of the United States Veteran Health Administrations. Dr. Taber has research grants from Veloxis, Merck, CareDx and is an Advisory Board Member for Veloxis and CareDx. Ms. Perry and Dr Soliman are on the editorial board for Renal Failure.
Similar articles
-
Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.Transplant Proc. 2020 Apr;52(3):829-835. doi: 10.1016/j.transproceed.2020.01.028. Epub 2020 Feb 27. Transplant Proc. 2020. PMID: 32113693
-
Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.Am J Transplant. 2019 Feb;19(2):573-584. doi: 10.1111/ajt.15183. Epub 2018 Dec 14. Am J Transplant. 2019. PMID: 30431703
-
Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.Transpl Infect Dis. 2018 Oct;20(5):e12964. doi: 10.1111/tid.12964. Epub 2018 Jul 20. Transpl Infect Dis. 2018. PMID: 29981174
-
Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.Transplantation. 2014 Mar 15;97(5):569-75. doi: 10.1097/01.tp.0000438197.38413.f2. Transplantation. 2014. PMID: 24398852
-
Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence.Transpl Infect Dis. 2021 Apr;23(2):e13483. doi: 10.1111/tid.13483. Epub 2020 Oct 22. Transpl Infect Dis. 2021. PMID: 33012092
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical